Table 1 Clinicopathological characteristics of 60 cases of TM9SF4 expression by immunohistochemisty
From: CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
Variable | n | TM9SF4 | P value | |
|---|---|---|---|---|
High(n = 47) | Low(n = 13) | |||
Age(y) | ||||
 <65(median) | 26 | 19 | 7 | 0.0642 |
  ≥ 65 | 34 | 28 | 6 |  |
PSA(ng/ml) | ||||
 <10 | 5 | 4 | 1 | 0.1744 |
 10 ~ 20 | 21 | 16 | 5 |  |
 >20 | 34 | 27 | 7 |  |
Gleason score | ||||
  ≤ 6 | 6 | 3 | 3 | 0.1708 |
 7 | 32 | 23 | 9 |  |
  ≥ 8 | 22 | 21 | 1 |  |
Pathological T Category | ||||
 pT1/2 | 30 | 20 | 10 | 0.0637 |
 pT3/4 | 30 | 26 | 4 |  |
Lymph node metastasis | ||||
 N0 | 50 | 39 | 11 | 0.4027 |
 N1 | 10 | 8 | 2 |  |
Stage classification | ||||
 I-II | 24 | 23 | 1 | 0.0364* |
 III-IV | 36 | 33 | 3 |  |